MSLN and cancer: Magnetic resonance imaging analysis of site-specific biotinylated NbG3a targeted streptavidin labeled iron oxides exerted a qualitative reduction in signal intensity within the subcutaneous OC xenograft one hours after injection in T2-weighted images, supporting the use of NbG3b for further preclinical development and translation to diagnostic and therapeutic applications in MSLN-expressing malignancies (36, 37).